New Birch Triterpene Research Offers Insights for EB Care
The research provides new clinical data for patients with epidermolysis bullosa to discuss with their doctors.
Updated on Oct. 15, 2026 in Allergies
Live Poll
Do you believe pharmaceutical companies are doing enough to develop treatments for rare diseases?
Chiesi Global Rare Diseases presented new research on birch triterpenes for the treatment of epidermolysis bullosa at the 14th Annual Conference of the Pediatric Dermatology Research Alliance. This development offers new clinical insights for those managing the rare skin condition.
Why it matters
Expanding the evidence base for treatments like birch triterpenes helps clinicians and patients better understand wound-management options for epidermolysis bullosa. This research provides updated data on the clinical use of the treatment, which is currently available in several international markets.
Chiesi Global Rare Diseases presented three posters detailing clinical experiences and mechanism-of-action data for birch triterpenes at a professional conference. The full scope of this research is still being evaluated, and outcomes are still being studied as the drug expands globally.
The players
Chiesi Global Rare Diseases
A division of the Chiesi Group focused on developing treatments for rare and orphan diseases.
Pediatric Dermatology Research Alliance
A research organization dedicated to advancing pediatric dermatology through collaborative research and clinical evidence.
The details
The treatment, known as FILSUVEZ, is applied topically as a 1 mm layer to the wound surface and covered with a dressing. Birch triterpenes function by supporting the wound-healing process, which is often compromised in patients with epidermolysis bullosa. These findings add to existing clinical data regarding the application of the therapy in dermatological care.
Timeline
• June 2022: The European Commission approved FILSUVEZ.
• September 2022: The UK Medicines and Healthcare products Regulatory Agency approved FILSUVEZ.
• December 2023: The FDA approved FILSUVEZ.
• May 5, 2026: FILSUVEZ was registered in Australia.
• October 15-17, 2026: The PeDRA Annual Conference took place.
Health Landscape
This research updates the clinical landscape following the regulatory approval of FILSUVEZ for epidermolysis bullosa. It follows a pattern of ongoing data generation that tracks the performance of the treatment as it becomes available to the global population of 500,000 affected patients.
For patients and caregivers managing epidermolysis bullosa, these findings highlight the importance of staying current on wound care protocols with a specialist. You should discuss with your physician whether new clinical data or treatment developments are relevant to your current care plan.
The takeaway
Ongoing research into birch triterpenes continues to refine how clinicians treat complex skin wounds associated with epidermolysis bullosa. Patients are encouraged to track developments in clinical wound care and have regular, focused conversations with their dermatologists about new evidence.
Further reading
For more information on the management of skin conditions, visit Allergies.
Live Poll
Do you believe pharmaceutical companies are doing enough to develop treatments for rare diseases?
